Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings

Oct 31, 2024 · Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings. The company disclosed the quarter's net sales nominally at $11.4 billion, $0.7 billion less than the forecasted …

$11
OFF

Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings

2 weeks from now

Oct 31, 2024 · Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings. The company disclosed the quarter's net sales nominally at $11.4 billion, $0.7 billion less than the forecasted …

yahoo.com

5%
OFF

Eli Lilly Shares Down 7.5% As Market Reacts To Slashed Q4 Forecast

2 weeks from now

16 hours ago · Shares of Eli Lilly are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024.The pharmaceutical giant expects …

yahoo.com

$11
OFF

Shares In Weight-loss Drugmaker Eli Lilly Fall On Disappointing Sales

2 weeks from now

Oct 30, 2024 · Eli Lilly’s third-quarter revenues were $11.4bn, falling short of analyst expectations of $12.2bn, the company said on Wednesday. Earnings per share were $1.18, below analyst …

ft.com

7%
OFF

Eli Lilly Shares Tumble After Cutting Its Sales Outlook. What It Means ...

2 weeks from now

15 hours ago · Shares plunged 7% after management said demand for its popular GLP-1 drugs did not meet expectations.

cnbc.com

6%
OFF

Eli Lilly Stock Tumbles After Drug Giant Misses Estimates And …

2 weeks from now

Oct 30, 2024 · The company's stock closed more than 6% lower on Wednesday. Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from …

nbcwashington.com

$1.18
OFF

Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock …

2 weeks from now

Oct 30, 2024 · Eli Lilly and Company LLY reported third-quarter 2024 adjusted earnings per share ("EPS") of $1.18, which missed the Zacks Consensus Estimate of $1.52 per share. In the year …

nasdaq.com

20%
OFF

Lilly Shares Tumble On Earnings Report That Falls Short Of Wall Street ...

2 weeks from now

Oct 30, 2024 · Revenue for the quarter was $11.43 billion, up 20%, but short of the $12.03 billion expected by a consensus of Wall Street analysts, according to Zack’s. Lilly posted adjusted …

greenfieldreporter.com

$2
OFF

Eli Lilly Misses Quarterly Profit Estimates; Shares Tumble

2 weeks from now

Oct 30, 2024 · Bengaluru: Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs and a $2.8 billion acquisition-related charge, …

indiatimes.com

20%
OFF

Eli Lilly Posts A Huge Earnings Miss. Should Investors Be Worried ...

2 weeks from now

Nov 6, 2024 · Eli Lilly's revenue grows by 20%, but falls short of estimates. Eli Lilly didn't have a bad quarter, but when perfection is priced into a stock, anything less than glorious results can …

nasdaq.com

$3.11
OFF

Eli Lilly Stock Tumbles As Q3 Sales, Profits Fall Well Short Of …

2 weeks from now

Eli Lilly said sales of Mounjaro more than doubled year-over-year to $3.11 billion, while Zepbound produced $1.26 billion in quarterly sales as it approaches its one-year anniversary of Food and ...

yahoo.com

$8.00
OFF

Updated January 2025 - 60 Photos & 34 Reviews - Yelp

2 weeks from now

Share. Save. Menu. Popular dishes. View full menu. $8.00. Ceviche. ... My wife and I heard about the food in this restaurant and it didn't disappoint. The place is small in size and humble …

yelp.com

FAQs about Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings Coupon?

Why are Eli Lilly shares down 76% today?

Shares of Eli Lilly (NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024. The pharmaceutical giant expects only $13.5 billion in revenue for Q4 2024, compared to the consensus estimate of $13.97 billion. ...

Why did Eli Lilly stock tumble 12%?

AJ Mast / Bloomberg via Getty Images Eli Lilly (LLY) shares tumbled 12% at the opening bell Wednesday after its third-quarter results fell well short of analysts' estimates and it lowered its full-year guidance. ...

Why did Eli Lilly lose $70 billion?

(Reuters) -Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand. Lilly shares were off 8%, wiping out nearly $70 billion from the Indianapolis-based drugmaker's market value. ...

Did Lilly miss earnings per share?

The company also missed earnings per share by a whopping 20%, reporting $1.18 per share versus Wall Street expectations of $1.51. Lilly's blockbuster weight-loss drug Zepbound and diabetes drug Mounjaro remain bright spots, as the GLP-1 drug portfolio remains a focal point of the company's earnings story. ...

Is Eli Lilly a 'hold' stock?

Eli Lilly's operational performance is strong, but shares are expensive, leading me to reaffirm a 'hold' rating despite potential upside from new drugs. Recent financial results show significant revenue and profit growth, driven by drugs like Zepbound and Mounjaro, but some older drugs are underperforming. ...